Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Small Cell Lung Carcinoma 6Neoplasms 4Breast Neoplasms 3Sarcoma 2Ovarian Neoplasms 2Neuroendocrine Tumors 2Mesothelioma 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Advanced Solid Tumors 2Advanced Solid Tumor 2Stomach Neoplasms 1Solid Tumors 1Recurrence 1Pancreatic Neoplasms 1Mesothelioma, Malignant 1Major Advanced Solid Tumors Other Than Colorectal 1Leukemia 1Glioblastoma 1Gastrointestinal Malignancies 1Gastro-enteropancreatic neuroendocrine tumor 1Endometrial Neoplasms 1Carcinoma, Ovarian Epithelial 1ADVANCED SOLID TUMORS 1

Interventions

durvalumab 7Carboplatin 7Docetaxel 6Paclitaxel 5Nivolumab 5talazoparib 4linifanib 4Cisplatin 4trifluridine tipiracil drug combination 3tremelimumab 3tislelizumab 3depatuxizumab 3ST 1481 3S 1 (combination) 3Panobinostat 3Gemcitabine 3zimberelimab 2toripalimab 2olaparib 2motesanib diphosphate 2mogamulizumab 2TAS-114 2Sorafenib 2Rifampin 2PM 01183 2Oxaliplatin 2MLN 8237 2Itraconazole 2Injections 2Erlotinib Hydrochloride 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Advanced Solid Tumors × PM 01183 × Clear all
NCT05063318 2025-09-02

Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors

PharmaMar

Phase 1 Completed
14 enrolled 20 charts
Other solid neoplasm

Advanced Solid Tumors

NCT02454972 2023-03-02

Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors

PharmaMar

Phase 2 Completed
345 enrolled 34 charts 1 FDA
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡